Celldex Therapeutics has successfully completed patient enrollment for its two global Phase III clinical studies—Embarq-Csu1 and Embarq-Csu2—of the innovative drug Barzolvolimab for chronic spontaneous urticaria.

Data: If BTC falls below $62,961, the cumulative long liquidation intensity on major CEXs will reach $1.638 billions.

Circle's pre-market gains expand to 21.6%, all three major U.S. stock index futures rise collectively

After the proposed transaction is completed, Blockchain Inc.'s shares are expected to be listed on the NYSE American under the ticker symbol "AIB".

Automotive service giant Driven Brands Holdings Inc. faces major financial turmoil